About the Program
The goal of the Ohio State University transplant hepatology fellowship program is to train physicians who will carry forward our values of leadership, education, and clinical excellence. Transplant hepatology fellows experience.
Program Details
Inpatient Training
Fellows will complete 8 weeks of inpatient service which includes acting as the attending for a resident service as well as management of an active consult ad post-transplant service. Fellows will complete 8 weeks of inpatient service which includes acting as the attending for a resident service as well as management of an active consult ad post-transplant service. Additionally, fellows with work closely with our surgery service including rotating with them 4 weeks of the year. Our transplant center performs 140 transplants each year including living liver donors, liver-kidney, and heart-liver.Outpatient Training
During outpatient rotations transplant fellows with have 2 general hepatology clinics and 2 post-transplant clinics per week. The focus of the general hepatology clinics are to see patients with a variety of liver conditions including those who may be referred for or are under evaluation for liver transplantation. Fellows will also have dedicated endoscopy time to miantain and develop their endoscopic skills. Additionally, there is dedicated time with the hepato-pathology team through one-on-one instruction and every other week conferences. There are also opportunities for time with interventional radiology for optional training in liver biopsies and to observe procedures such as TIPS/TACE/BRTO.
Research
Fellows participate in a variety of ongoing or new clinical research projects related to liver disease or liver transplantation.
Curriculum
ACGME Fellowship Requirements
- Liver biopsies (requirement for 20 ended 2022) now optional
- 200 liver pathology slides
- Scholarly activity
- Attendance at AASLD
- 3 Liver transplants
- 1-3 procurements (of note the program requirement is 1 but to become a director of liver transplant the requirement is 3)
- Attendance at Patient Selection Committee (PSC) every Monday 8AM
- Attendance at Liver pathology conference 2nd and 4th Mondays of the month at 12PM
- Attendance at Liver tumor board Friday 730 AM
- Lecture series for the general GI fellows on hepatology topics
- Surgical experience
Lectures to fellows
- Autoimmune diseases of the liver
- Evaluation of the outpatient liver patient
- Management of portal hypertension
- Liver transplant- indications and complications
- Immune suppression
- Viral hepatitis
Sample weekly schedule
Monday morning: Livery biopsy / Path
Monday afternoon: HCC clinic
Tuesday morning: Clinic
Tuesday afternoon: Tx clinic
Wednesday morning: Research
Wednesday afternoon: Research
Thursday morning: Endo
Thursday afternoon: Wellner clinic
Friday morning: Tx clinic
Friday afternoon:Endo
Reading list
The goal of the fellowship is to provide a well-rounded education both through patient driven clinical experience as well as didactic lectures and a selection of suggested readings based on the contents of the ACGME Transplant Hepatology board exam. The Outline below is meant to guide fellows and provide suggested topics with the understanding that education is a dynamic process, and many topics and readings may be shaped by the clinical experience of the fellows on rotation.
- Quarter 1: Transplant, pathology, Acute liver failure, Immunology
- Quarter 2: Viral hepatitis, Autoimmune liver diseases, Alcoholic liver disease
- Quarter 3: Metabolic diseases, Pediatric liver diseases, Liver cancers
- Quarter 4: Pregnancy and liver disease, statistics, outpatient hepatology
Application Process
We are accepting applications for the 2020-2021 academic year and beyond.
Requirements- Completion of a three-year accredited fellowship in gastroenterology
- Meet the requirements for board eligibility in gastroenterology at the time of commencement of the fellowship
- U.S. citizen, permanent resident or J-1 Visa status
- Valid Ohio medical license by commencement of training
Application Must Include:
- Application (PDF)
- CV
- Letter of interest
- Three letters of recommendation
Mail or email your application and accompanying documents to:
Casey Suich
Program Coordinator
Casey.Suich@osumc.edu
The Ohio State University Wexner Medical Center
Division of Gastroenterology, Hepatology and Nutrition
395 W. 12th Avenue, Room 346A
Columbus, OH 43210
Meet the Program Director:
Research and publications
Olivo, Raquel, James V. Guarrera, and Nikolaos T. Pyrsopoulos. "Liver transplantation for acute liver failure." Clinics in liver disease 22.2 (2018): 409-417. https://pubmed.ncbi.nlm.nih.gov/29605075/
Ramzan, Moazma, et al. "Comparison of CLIF-C ACLF score and MELD score in predicting ICU mortality in patients with acute-on-chronic liver failure." Cureus 12.2 (2020). https://pubmed.ncbi.nlm.nih.gov/32226688/
Zaccherini, Giacomo, Emmanuel Weiss, and Richard Moreau. "Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment." JHEP Reports 3.1 (2021): 100176. https://pubmed.ncbi.nlm.nih.gov/33205036/
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.32689
Marot, Astrid, Christophe Moreno, and Pierre Deltenre. "Liver transplant for alcoholic hepatitis: a current clinical overview." Expert review of gastroenterology & hepatology 14.7 (2020): 591-600. https://pubmed.ncbi.nlm.nih.gov/32511039/
Lindor, Keith D., et al. "Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases." Hepatology 69.1 (2019): 394-419. https://www.aasld.org/sites/default/files/2022-04/PracticeGuidelines-PBC-November2018_1.pdf
Chapman, Roger, et al. "Diagnosis and management of primary sclerosing cholangitis." Hepatology (Baltimore, Md.)51.2 (2010): 660-678. https://europepmc.org/article/med/20101749
Alam, Seema, and Bikrant Bihari Lal. "Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies." World Journal of Hepatology 14.1 (2022): 98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790387/
Sibulesky, Lena. "Normal liver anatomy." Clinical liver disease 2.Suppl 1 (2013): S1. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6448666/
Duke pathology slides
https://pathology.oit.duke.edu/siteParts/avaps/06.15.1_Liver_Pathology_Final.pdf
Selection and evaluation
Levitsky, J., et al. "The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation." (2017): 2790-2802. https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.14381Lai, Jennifer C., et al. "Development of a novel frailty index to predict mortality in patients with end‐stage liver disease." Hepatology 66.2 (2017): 564-574. https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.29219
Miller, Charles M., et al. "The international liver transplantation society living donor liver transplant recipient guideline." Transplantation 101.5 (2017): 938. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642345/
Surgical approach
Makowka, Leonard, et al. "Surgical technique of orthotopic liver transplantation." Gastroenterology Clinics of North America 17.1 (1988): 33-51. https://www.sciencedirect.com/science/article/pii/S0889855321003423Perioperative complications
Mohanraj, B. Sharmila, Amol S. Rangnekar, and Joseph G. Timpone. "Infections in liver transplantation." Principles and Practice of Transplant Infectious Diseases. Springer, New York, NY, 2019. 41-72. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120017/Amara, Dominic, et al. "Surgical complications after living and deceased donor liver transplant: The NSQIP transplant experience." Clinical Transplantation (2022): e14610. https://doi.org/10.1111/ctr.14610
Baheti, Akshay D., et al. "Surgical techniques and imaging complications of liver transplant." Radiologic Clinics 54.2 (2016): 199-215. https://pubmed.ncbi.nlm.nih.gov/26896220/
Kochhar, Gursimran, et al. "Biliary complications following liver transplantation." World Journal of Gastroenterology: WJG19.19 (2013): 2841. https://pubmed.ncbi.nlm.nih.gov/23704818/
Chen, Jun, et al. "Surgical and endovascular treatment of hepatic arterial complications following liver transplant." Clinical Transplantation 28.12 (2014): 1305-1312. https://pubmed.ncbi.nlm.nih.gov/25091402/
Kelly, Deirdre A., et al. "Long‐term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation." Liver Transplantation 19.8 (2013): 798-8 https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/lt.23697
Kamal, Natasha, Pallavi Surana, and Christopher Koh. "Liver disease in patients with cystic fibrosis." Current opinion in gastroenterology 34.3 (2018): 146. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7232742/
Rake, Jan, et al. "Guidelines for management of glycogen storage disease type I–European Study on Glycogen Storage Disease Type I (ESGSD I)." European journal of pediatrics 161.1 (2002): S112-S119.
Ross, Katalin M., et al. "Dietary management of the glycogen storage diseases: evolution of treatment and ongoing controversies." Advances in Nutrition 11.2 (2020): 439-446.
Ross, Katalin M., et al. "Safety and efficacy of chronic extended release cornstarch therapy for glycogen storage disease type I." JIMD Reports, Volume 26. Springer, Berlin, Heidelberg, 2015. 85-90.
Strong, Alanna, et al. "Hepatic Manifestations of Urea Cycle Disorders." Clinical Liver Disease 18.4 (2021): 198. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.1115
Palumbo, Chiara Saroli, and Michael L. Schilsky. "Clinical practice guidelines in Wilson disease." Annals of translational medicine 7.Suppl 2 (2019). https://pubmed.ncbi.nlm.nih.gov/31179302/
Bacon, Bruce R., et al. "Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases." Hepatology (Baltimore, Md.) 54.1 (2011): 328. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/
Singal, Ashwani K., et al. "Liver transplantation in the management of porphyria." Hepatology 60.3 (2014): 1082-1089. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498564/
European Association For The Study Of The Liver. "EASL Clinical Practice Guidelines on nutrition in chronic liver disease." Journal of hepatology 70.1 (2019): 172-193. https://pubmed.ncbi.nlm.nih.gov/30144956/
Hilscher, Moira B., et al. "Fontan-associated liver disease." Hepatology 75.5 (2022): 1300-1321. https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.32406
IVIG and serologies
King, Catherine, Una Sutton-Fitzpatrick, and Julieanne Houlihan. "Transient derangements in Hepatitis B serology in patients post-intravenous immunoglobulin therapy—a case-based review." Irish Journal of Medical Science (1971-) 189.2 (2020): 617-620. https://pubmed.ncbi.nlm.nih.gov/31643027/
Arnold, Donald M., et al. "Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia." Transfusion 50.12 (2010): 2577-2581.
Hui, Edwin Pun. "Immunoglobulin therapy and passive transfer of anti-HBc: too often forgotten." The Lancet Haematology 5.10 (2018): e437-e438.
Polycystic liver disease
van Aerts, Rene MM, et al. "Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease." Gastroenterology 157.2 (2019): 481-491.
Gevers, Tom JG, et al. "Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial." Liver International 35.5 (2015): 1607-1614.
Neijenhuis, M.K., Gevers, T.J., Nevens, F. et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment Pharmacol Ther. 2015; 42: 591–598
Short telomere syndrome
Schratz, Kristen E. "Extrahematopoietic manifestations of the short telomere syndromes." Hematology 2014, the American Society of Hematology Education Program Book 2020.1 (2020): 115-122. https://ashpublications.org/hematology/article/2020/1/115/474343/Extrahematopoietic-manifestations-of-the-short
Armanios, Mary, and Elizabeth H. Blackburn. "The telomere syndromes." Nature Reviews Genetics 13.10 (2012): 693-704. https://pubmed.ncbi.nlm.nih.gov/22965356/
Kalra, Avash, and J. P. Norvell. "Cause for confusion: noncirrhotic hyperammonemic encephalopathy." Clinical Liver Disease 15.6 (2020): 223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326631/
Iwakiri, Yasuko, and Jonel Trebicka. "Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy." JHEP Reports 3.4 (2021): 100316. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318926/
Koch, David G., and Michael B. Fallon. "Hepatopulmonary syndrome." Clinics in liver disease 18.2 (2014): 407-420. https://pubmed.ncbi.nlm.nih.gov/24679503/
Aggarwal, N., et al. "Non-cirrhotic portal hypertension in pregnancy." International journal of gynecology & obstetrics 72.1 (2001): 1-7.
Aggarwal, Neelam, et al. "Pregnancy with portal hypertension." Journal of clinical and experimental hepatology 4.2 (2014): 163-171.
Sarkar, Monika, et al. "Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases." Hepatology (Baltimore, Md.) (2020). https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.31559
Goel, Ashish, et al. "Pregnancy-related liver disorders." Journal of Clinical and Experimental Hepatology 4.2 (2014): 151-162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116710/
Charlton, Michael, et al. "International liver transplantation society consensus statement on immunosuppression in liver transplant recipients." Transplantation 102.5 (2018): 727-743. https://journals.lww.com/transplantjournal/Fulltext/2018/05000/International_Liver_Transplantation_Society.13.aspx?casa_token=om4erDyDLawAAAAA:qywBkW1eG20sBVipCyYPW8Ucd6mPqFBzoOtRZ99ftcGzSQHet_4ZzPOBrcfrH6572LIodtULEGDnknBYkLjexw
Demetris, Anthony J., et al. "Banff schema for grading liver allograft rejection: an international consensus document." Hepatology 25.3 (1997): 658-663. https://mayoclinic.pure.elsevier.com/en/publications/banff-schema-for-grading-liver-allograft-rejection-an-internation
Demetris, A. Jake, et al. "2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody‐mediated rejection." (2016): 2816-2835. https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.13909
Hackl, Christina, et al. "Liver transplantation for malignancy: current treatment strategies and future perspectives." World Journal of Gastroenterology: WJG 20.18 (2014): 5331. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017048/
Al‐Adra, David P., et al. "Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement." American Journal of Transplantation 21.2 (2021): 460-474. https://onlinelibrary.wiley.com/doi/10.1111/ajt.16318
Rosen, Charles B., Julie K. Heimbach, and Gregory J. Gores. "Liver transplantation for cholangiocarcinoma." Transplant International 23.7 (2010): 692-697. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1432-2277.2010.01108.x
Hepatitis C
Hepatitis C treatment guidelines by AASLD and the IDSA https://www.hcvguidelines.org/
Ghany, Marc G., Timothy R. Morgan, and AASLD‐IDSA hepatitis C guidance panel. "Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection." Hepatology 71.2 (2020): 686-721. https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31060
Hepatitis B
Terrault, Norah A., et al. "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance." Hepatology 67.4 (2018): 1560-1599. https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.29800
Spyrou, Elias, Coleman I. Smith, and Marc G. Ghany. "Hepatitis B: Current status of therapy and future therapies." Gastroenterology Clinics 49.2 (2020): 215-238. https://pubmed.ncbi.nlm.nih.gov/32389360/
Ekpanyapong, Sirina, and K. Rajender Reddy. "Hepatitis B virus reactivation: what is the issue, and how should it be managed?." Clinics in Liver Disease 24.3 (2020): 317-333. https://pubmed.ncbi.nlm.nih.gov/32620274/
Huang, Daniel Q., Guan Sen Kew, and Seng Gee Lim. "Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer." Clinics in Liver Disease 25.4 (2021): 763-784. https://pubmed.ncbi.nlm.nih.gov/34593152/
HAV, HDV, HEV
Abutaleb, Ameer, and Shyam Kottilil. "Hepatitis A: epidemiology, natural history, unusual clinical manifestations, and prevention." Gastroenterology Clinics 49.2 (2020): 191-199. https://pubmed.ncbi.nlm.nih.gov/32389358/
Niro, Grazia A., et al. "Hepatitis delta virus: From infection to new therapeutic strategies." World Journal of Gastroenterology 27.24 (2021): 3530. https://pubmed.ncbi.nlm.nih.gov/34239267/
Hercun, Julian, Christopher Koh, and Theo Heller. "Hepatitis delta: prevalence, natural history, and treatment options." Gastroenterology Clinics 49.2 (2020): 239-252. https://pubmed.ncbi.nlm.nih.gov/32389361/
Aslan, Abdullah Tarık, and Hatice Yasemin Balaban. "Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment." World journal of gastroenterology 26.37 (2020): 5543. https://pubmed.ncbi.nlm.nih.gov/33071523/
Other viral infections
Jothimani, Dinesh, et al. "COVID-19 and the liver." Journal of hepatology 73.5 (2020): 1231-1240. https://www.journal-of-hepatology.eu/article/S0168-8278(20)30377-9/fulltext
Faruqui, Saamia, et al. "Cholangiopathy after severe COVID-19: clinical features and prognostic implications." Official journal of the American College of Gastroenterology| ACG116.7 (2021): 1414-1425. https://pubmed.ncbi.nlm.nih.gov/33993134/
Spengler, Ulrich, Hans-Peter Fischer, and Wolfgang H. Caselmann. "Liver Disease Associated with Viral Infections." Zakim and Boyer's Hepatology (2012): 629. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152320/